New Recombinant Standard for FVIII Concentrate Gives Same Results as Previous Plasma Derived Standards on a Range of FVIII Products

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Thromb Haemost 2000; 83(05): 789-790
DOI: 10.1055/s-0037-1613913

Letters to the Editor

Schattauer GmbH

Maria Elisa Albertengo

¹From Instituto Nacional de Medicamentos, Buenos Aires, Argentina

,

Trevor W. Barrowcliffe

²National Institute for Biological Standards and Control, Potters Bar, UK

,

Liliana Oliva

¹From Instituto Nacional de Medicamentos, Buenos Aires, Argentina

,

Sally Bevan

²National Institute for Biological Standards and Control, Potters Bar, UK

,

Sanjeev Raut

²National Institute for Biological Standards and Control, Potters Bar, UK

Further Information

Received 25 October 1999

Accepted after resubmission 18 January 2000

Publication Date:
08 December 2017 (online)

References
1 Lee C. Recombinant clotting factors in the treatment of hemophilia. Thromb Haemost 1999; 82 (State of the Art): 516-24.

Article in Thieme Connect PubMed Google Scholar
2 Barrowcliffe TW. Factor VIII and Factor IX Sub-committee. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost 1993; 70 (05) 876-7.

Article in Thieme Connect PubMed Google Scholar
3 Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assignment of recombinant FVIII concentrates. Haemophilia 1998; 04: 634-40.

Crossref PubMed Google Scholar
4 Barrowcliffe TW. Standardization and assay. Semin Thromb Hemost 1993; 19 (01) 73-9.

Article in Thieme Connect PubMed Google Scholar
5 Raut S, Heath A, Barrowcliffe TW. 6th International Standard for FVIII concentrate. NIBSC unpublished report.

PubMed Google Scholar
6 Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 04: 646-50.

Crossref PubMed Google Scholar